The global leukapheresis market size is calculated at USD 243.83 million in 2025 and is forecasted to reach around USD 628.80 billion by 2034, accelerating at a CAGR of 11.10% from 2025 to 2034. The North America market size surpassed USD 81.20 million in 2024 and is expanding at a CAGR of 11.24% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Leukapheresis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Leukapheresis Market, by Product
8.1.1 Leukapheresis Devices
8.1.1.1. Market Revenue and Forecast
8.1.2. Centrifugal Devices
8.1.2.1. Market Revenue and Forecast
8.1.3. Membrane Separators
8.1.3.1. Market Revenue and Forecast
8.1.4. Leukapheresis Disposables
8.1.4.1. Market Revenue and Forecast
9.1. Leukapheresis Market, by Application
9.1.1. Research Application
9.1.1.1. Market Revenue and Forecast
9.1.2. Cancer Research
9.1.2.1. Market Revenue and Forecast
9.1.3. Immunology Research
9.1.3.1. Market Revenue and Forecast
9.1.4. Separator
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
9.1.6. Therapeutics Application
9.1.6.1. Market Revenue and Forecast
9.1.7. Hematologic Disorders
9.1.7.1. Market Revenue and Forecast
9.1.8. Autoimmune Diseases
9.1.8.1. Market Revenue and Forecast
9.1.9. Others
9.1.9.1. Market Revenue and Forecast
10.1. Leukapheresis Market, by End-use
10.1.1. Blood Centers
10.1.1.1. Market Revenue and Forecast
10.1.2. Pharmaceutical and Biotechnology Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. Hospitals and Clinics
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by End-use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by End-use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by End-use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by End-use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by End-use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by End-use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by End-use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by End-use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by End-use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by End-use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by End-use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by End-use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by End-use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by End-use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by End-use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by End-use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by End-use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by End-use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by End-use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by End-use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by End-use
12.1. Charles River Laboratories International, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Adacyte Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AllCells, LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Asahi Kasei Medical
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Haemonetics Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Macopharma
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cerus Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SB-Kawasumi Laboratories, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. StemExpress, LLC.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Haemonetics Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample